Hemadex Technology Studies Presented at NATA Symposium
Research Results Show Profound Properties of Medafor's Topical Hemostatic Beads

Minneapolis, Minn., April 2001 - Medafor, Inc., is proud to announce that its MPH™ (Microporous Polysaccharide Hemospheres) technology was the subject of two studies presented at the Network for Advancement of Transfusion Alternatives (NATA) Symposium last month in Berlin.

These studies evaluated the use of Medafor's topical hemostatic beads-degradable polysaccharide microspheres with micro-replicated porous channels-as frozen-plasma and in-vitro coagulants, using thromboelastography (TEG) detection. Key conclusions of the studies are as follows:

After the addition of hemostatic beads, enhanced coagulation was evident on fresh frozen plasma samples. The pore size of the beads enabled water absorption and hyperconcentration of albumin, coagulation factors and other protein and cellular components of the blood. The biochemical effect on coagulation and the combined effect on platelets are the subject of further study.

Using TEG to determine coagulation function after ex-vivo addition of the hemostatic beads, showed an excellent correlation between bead dosage and the mass and angle of the recalcified, citrated blood. Hemostatic beads also had some impact on platelet function as well as enhanced fibrin formulation. In addition, the beads appeared to accelerate the coagulation enzymatic reaction rate. In-vitro coagulation profiles also provided insight into the profound properties of Medafor's topical hemostatic bead technology.

"We're pleased to see such positive results and indications from the studies," stated Dr. James Drake, Chief Scientist at Medafor. "We're looking forward to participating in further studies which will help us to formulate market-specific applications and delivery systems for our MPH technology."

Medafor, Inc., is a privately held Minnesota corporation, founded in 1999 to develop and market groundbreaking hemostatic technology based on engineered biopolymeric microporous particles. The company has segmented target markets for the initial penetration of its products and is in the process of preparing submissions for appropriate regulatory clearances.

Statements made in this release have not been evaluated by the FDA or any other regulating body, and Medafor's products are not currently available for use in humans. This release may contain forward-looking statements based on current expectations of future events. If underlying assumptions prove inaccurate, or unforeseen risks or circumstances materialize, actual results could vary materially from expectations and projections stated herein. The company assumes no obligation to update any forward-looking statements as a result of new information or future developments. BACK.